The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus

@inproceedings{Sthoeger2013TheTP,
  title={The Tolerogenic Peptide, hCDR1, Down-Regulates the Expression of Interferon-α in Murine and Human Systemic Lupus Erythematosus},
  author={Zev Moshe Sthoeger and Heidy Zinger and Amir Sharabi and Ilan Asher and Edna Mozes},
  booktitle={PloS one},
  year={2013}
}
BACKGROUND The tolerogenic peptide, hCDR1, ameliorated manifestations of systemic lupus erythematosus (SLE) via the immunomodulation of pro-inflammatory and immunosuppressive cytokines and the induction of regulatory T cells. Because type I interferon (IFN-α) has been implicated to play a role in SLE pathogenesis, we investigated the effects of hCDR1 on IFN-α in a murine model of SLE and in human lupus. METHODOLOGY PRINCIPAL FINDINGS (NZBxNZW)F1 mice with established SLE were treated with… CONTINUE READING
11 Citations
50 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Sharabi A (2010) A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus

  • E Mozes
  • Autoimmun Rev
  • 2010
Highly Influential
7 Excerpts

Similar Papers

Loading similar papers…